Epizyme, Inc. (NASDAQ:EPZM) insider Jeffery Kutok sold 2,029 shares of the firm’s stock in a transaction that occurred on Monday, April 5th. The stock was sold at an average price of $8.80, for a total transaction of $17,855.20. Following the transaction, the insider now owns 54,028 shares in the company, valued at $475,446.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Epizyme stock opened at $8.44 on Thursday. Epizyme, Inc. has a one year low of $7.44 and a one year high of $22.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 8.71 and a current ratio of 8.95. The business has a fifty day moving average of $9.21 and a two-hundred day moving average of $11.31. The company has a market cap of $859.07 million, a P/E ratio of -3.78 and a beta of 1.76.
Epizyme (NASDAQ:EPZM) last released its earnings results on Monday, February 22nd. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.06). Epizyme had a negative net margin of 1,899.35% and a negative return on equity of 83.45%. The business had revenue of $8.38 billion during the quarter, compared to analyst estimates of $6.55 million. Epizyme’s quarterly revenue was up 95.0% compared to the same quarter last year. Sell-side analysts predict that Epizyme, Inc. will post -2.23 EPS for the current year.
EPZM has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Tuesday, February 9th. Wedbush reaffirmed an “outperform” rating on shares of Epizyme in a report on Tuesday, February 23rd. Credit Suisse Group began coverage on Epizyme in a report on Tuesday, March 30th. They set an “outperform” rating and a $13.00 price target for the company. Morgan Stanley reaffirmed an “equal weight” rating and set a $14.00 price target on shares of Epizyme in a report on Wednesday, March 3rd. Finally, SVB Leerink reaffirmed a “market perform” rating on shares of Epizyme in a report on Friday, February 5th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Epizyme currently has an average rating of “Buy” and an average target price of $16.38.
A number of institutional investors have recently added to or reduced their stakes in the business. DekaBank Deutsche Girozentrale lifted its holdings in Epizyme by 54.5% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 32,300 shares of the biopharmaceutical company’s stock valued at $370,000 after acquiring an additional 11,400 shares during the period. Norges Bank acquired a new stake in Epizyme in the fourth quarter valued at $11,335,000. UBS Asset Management Americas Inc. lifted its holdings in Epizyme by 12.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 71,217 shares of the biopharmaceutical company’s stock valued at $773,000 after acquiring an additional 8,114 shares during the period. Principal Financial Group Inc. lifted its holdings in Epizyme by 17.6% in the fourth quarter. Principal Financial Group Inc. now owns 37,572 shares of the biopharmaceutical company’s stock valued at $408,000 after acquiring an additional 5,611 shares during the period. Finally, Voloridge Investment Management LLC acquired a new stake in Epizyme in the fourth quarter valued at $1,998,000. 89.82% of the stock is owned by institutional investors.
Epizyme Company Profile
Epizyme, Inc, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients.
Further Reading: What is the price-sales ratio?
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.